Update (June 8, 2026): First Multicenter RCT of Imepitoin in Feline Idiopathic Epilepsy

TL;DR

A multicenter, single-blinded, randomized, placebo-controlled trial published in 2026 reports a 62% responder rate for imepitoin in cats with idiopathic epilepsy — the first such RCT in the species — while phenobarbital showed a numerically higher 90% responder rate and greater seizure-day reduction.

What just dropped

• Charalambous M et al. (2026, Front Vet Sci) published results of a multicenter, single-blinded, randomized and placebo-controlled trial evaluating imepitoin vs. phenobarbital in 37 cats with feline idiopathic epilepsy over 15 weeks (PMID 41728120, https://pubmed.ncbi.nlm.nih.gov/41728120/)
• Imepitoin: 62% responder rate (>50% reduction in monthly seizure frequency); monthly seizure frequency decreased from mean 6.1 to 3.0 (P = 0.028); adverse effects in 88% of cats (predominantly ataxia and elevated ALT)
• Phenobarbital: 90% responder rate; significant reductions in both seizure frequency (P = 0.0026) and seizure days (P = 0.0011); time to first post-treatment seizure significantly longer than both imepitoin and placebo
• Between-group comparison: seizure day reduction was significantly higher for phenobarbital vs. imepitoin (P = 0.036); no significant difference in responder rate (P = 0.1) or overall seizure frequency reduction (P = 0.13)
• No licensed antiseizure drug is currently available in Europe for cats; this is the first published placebo-controlled trial addressing this gap

Context

Imepitoin (Pexion) holds EMA authorization (EMEA/V/C/002543) (https://www.ema.europa.eu/en/medicines/veterinary/EPAR/pexion) for canine idiopathic epilepsy, where it functions as a low-affinity partial agonist at the benzodiazepine binding site of GABA-A receptors. Its use in cats has been off-label and largely anecdotal, with no prior placebo-controlled trial data. The Charalambous 2026 trial is the first to provide randomized efficacy and safety data in cats.

The finding that phenobarbital outperformed imepitoin on seizure day reduction and time to first seizure, while both produced roughly similar overall responder rates, suggests that phenobarbital remains the more potent antiseizure option in cats — consistent with decades of clinical experience. The imepitoin result (62% responder rate, significant seizure frequency reduction) is nonetheless clinically meaningful for cases where phenobarbital is not preferred due to concerns about sedation or hepatotoxicity monitoring burden.

What this changes in imepitoin-canine-idiopathic-epilepsy (https://www.thevoyage.ai/forvets/knowledge/imepitoin-canine-idiopathic-epilepsy)

This trial does not alter the canine evidence base for imepitoin but establishes a reference point for off-label feline use. Clinicians who consider imepitoin in cats with idiopathic epilepsy now have a single multicenter RCT showing a 62% responder rate with a 15-week observation window — along with a high (88%) adverse effect rate dominated by ataxia and elevated ALT, which differs somewhat from the canine adverse effect profile. The absence of a licensed feline antiseizure drug in Europe creates the clinical context in which this evidence will be most frequently applied.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-08-imepitoin-feline-epilepsy

References

1. Charalambous M, Tipold A, Volk HA, et al. Antiseizure monotherapy with imepitoin or phenobarbital in feline idiopathic epilepsy: a multicenter, single-blinded, randomized and placebo-controlled study. Front Vet Sci. 2026;13:1770972. https://pubmed.ncbi.nlm.nih.gov/41728120/
2. Pexion (imepitoin) — European Medicines Agency product page. EMEA/V/C/002543. Last updated October 2025. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/pexion

Related reads

• Imepitoin Canine Idiopathic Epilepsy